KR20080045279A - C-fms 키나제 저해제로서의5-옥소-5,8-디하이드로-피리도-피리미딘 - Google Patents
C-fms 키나제 저해제로서의5-옥소-5,8-디하이드로-피리도-피리미딘 Download PDFInfo
- Publication number
- KR20080045279A KR20080045279A KR1020087008697A KR20087008697A KR20080045279A KR 20080045279 A KR20080045279 A KR 20080045279A KR 1020087008697 A KR1020087008697 A KR 1020087008697A KR 20087008697 A KR20087008697 A KR 20087008697A KR 20080045279 A KR20080045279 A KR 20080045279A
- Authority
- KR
- South Korea
- Prior art keywords
- oxo
- dihydro
- pyrimidine
- pyrido
- carboxylic acid
- Prior art date
Links
- 0 *C(CC1)C*1I Chemical compound *C(CC1)C*1I 0.000 description 20
- SFKWGKOMXONURD-UHFFFAOYSA-N CC(C1)NC(C)CN1c(cc1)ccc1Nc1ncc(C(C(C(N)=O)=CN2C3=CC(CCC4)=C4CC3)=O)c2n1 Chemical compound CC(C1)NC(C)CN1c(cc1)ccc1Nc1ncc(C(C(C(N)=O)=CN2C3=CC(CCC4)=C4CC3)=O)c2n1 SFKWGKOMXONURD-UHFFFAOYSA-N 0.000 description 1
- JYURXLFYRONLAX-UHFFFAOYSA-N CC(C1)NC(C)CN1c(cc1)ccc1Nc1ncc(C(C(C(NC)=O)=CN2c3ccc(CCC4)c4c3)=O)c2n1 Chemical compound CC(C1)NC(C)CN1c(cc1)ccc1Nc1ncc(C(C(C(NC)=O)=CN2c3ccc(CCC4)c4c3)=O)c2n1 JYURXLFYRONLAX-UHFFFAOYSA-N 0.000 description 1
- SMCZPZKZVMUPAH-UHFFFAOYSA-O CC(C1)[NH2+]C(C)CN1c1cc(Nc2ncc(C(C(C(NC)=O)=CN3c4ccc(CCC5)c5c4)=O)c3n2)ccc1 Chemical compound CC(C1)[NH2+]C(C)CN1c1cc(Nc2ncc(C(C(C(NC)=O)=CN3c4ccc(CCC5)c5c4)=O)c3n2)ccc1 SMCZPZKZVMUPAH-UHFFFAOYSA-O 0.000 description 1
- HZXHFRYFFYOZNP-UHFFFAOYSA-N CCNC(C1=CN(C2CCCCC2)c2nc(Nc3cccc(N4CCN(C)CC4)c3)ncc2C1=O)=O Chemical compound CCNC(C1=CN(C2CCCCC2)c2nc(Nc3cccc(N4CCN(C)CC4)c3)ncc2C1=O)=O HZXHFRYFFYOZNP-UHFFFAOYSA-N 0.000 description 1
- SAGRWAKYPQJNMH-UHFFFAOYSA-N CCNC(C1=CN(c2cc(CCC3)c3cc2)c2nc(Nc(cc3)ccc3N3CCNCC3)ncc2C1=O)=O Chemical compound CCNC(C1=CN(c2cc(CCC3)c3cc2)c2nc(Nc(cc3)ccc3N3CCNCC3)ncc2C1=O)=O SAGRWAKYPQJNMH-UHFFFAOYSA-N 0.000 description 1
- IXHJCUXDKKXMGP-UHFFFAOYSA-N CCNC(C1=CN(c2cc(CCC3)c3cc2)c2nc(Nc3ccc(CN4CCN(C)CC4)cc3)ncc2C1=O)=O Chemical compound CCNC(C1=CN(c2cc(CCC3)c3cc2)c2nc(Nc3ccc(CN4CCN(C)CC4)cc3)ncc2C1=O)=O IXHJCUXDKKXMGP-UHFFFAOYSA-N 0.000 description 1
- BAUZQGVHGIMEHS-UHFFFAOYSA-N CCNC(C1=CN(c2ccc(CC=C3)c3c2)c(nc(Nc2ccc(CCN3CCN(C)CC3)cc2)nc2)c2C1=O)=O Chemical compound CCNC(C1=CN(c2ccc(CC=C3)c3c2)c(nc(Nc2ccc(CCN3CCN(C)CC3)cc2)nc2)c2C1=O)=O BAUZQGVHGIMEHS-UHFFFAOYSA-N 0.000 description 1
- VETWSCYIJAHHGR-UHFFFAOYSA-N CCNC(C1=CN(c2ccc(CCC3)c3c2)c(nc(Nc2ccc(C3CCNCC3)cc2)nc2)c2C1=O)=O Chemical compound CCNC(C1=CN(c2ccc(CCC3)c3c2)c(nc(Nc2ccc(C3CCNCC3)cc2)nc2)c2C1=O)=O VETWSCYIJAHHGR-UHFFFAOYSA-N 0.000 description 1
- BEVVJWZPWXBPBH-UHFFFAOYSA-N CCNC(C1=CN(c2ccc(CCC3)c3c2)c2nc(Nc3cc(N4CCNCC4)ccc3)ncc2C1=O)=O Chemical compound CCNC(C1=CN(c2ccc(CCC3)c3c2)c2nc(Nc3cc(N4CCNCC4)ccc3)ncc2C1=O)=O BEVVJWZPWXBPBH-UHFFFAOYSA-N 0.000 description 1
- WFBYKPZOXWZWDH-UHFFFAOYSA-N CCOC(C1=CN(c2ccc(CCC3)c3c2)c2nc(Nc(cc3)ccc3F)ncc2C1=O)=O Chemical compound CCOC(C1=CN(c2ccc(CCC3)c3c2)c2nc(Nc(cc3)ccc3F)ncc2C1=O)=O WFBYKPZOXWZWDH-UHFFFAOYSA-N 0.000 description 1
- SHCFJIXSPWRTLY-UHFFFAOYSA-N CN(CC1)CCN1c(cc1)ccc1Nc1ncc(C(C(C(N)=O)=CN2c3ccc(CCC4)c4c3)=O)c2n1 Chemical compound CN(CC1)CCN1c(cc1)ccc1Nc1ncc(C(C(C(N)=O)=CN2c3ccc(CCC4)c4c3)=O)c2n1 SHCFJIXSPWRTLY-UHFFFAOYSA-N 0.000 description 1
- ULZCOWMSBOJCLT-UHFFFAOYSA-N CN(CC1)CCS1(=O)=O Chemical compound CN(CC1)CCS1(=O)=O ULZCOWMSBOJCLT-UHFFFAOYSA-N 0.000 description 1
- QMJWLZYVHWHKFD-UHFFFAOYSA-N CN(CC1)CS1=O Chemical compound CN(CC1)CS1=O QMJWLZYVHWHKFD-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N CN(CCC1)C1=O Chemical compound CN(CCC1)C1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- VWIIJDNADIEEDB-UHFFFAOYSA-N CN(CCO1)C1=O Chemical compound CN(CCO1)C1=O VWIIJDNADIEEDB-UHFFFAOYSA-N 0.000 description 1
- KLHJDCUHOKZNOP-UHFFFAOYSA-N CN1CCN(CCc(cc2)ccc2Nc2ncc(C(C(C(N)=O)=CN3c4ccc(CCC5)c5c4)=O)c3n2)CC1 Chemical compound CN1CCN(CCc(cc2)ccc2Nc2ncc(C(C(C(N)=O)=CN3c4ccc(CCC5)c5c4)=O)c3n2)CC1 KLHJDCUHOKZNOP-UHFFFAOYSA-N 0.000 description 1
- DGYVIUKQSWPZCL-UHFFFAOYSA-N CN1CSCC1 Chemical compound CN1CSCC1 DGYVIUKQSWPZCL-UHFFFAOYSA-N 0.000 description 1
- PWUBGUGRNSACJG-UHFFFAOYSA-N CNC(C1=CN(c2cc(CCC3)c3cc2)C2=NC(Nc(cc3)ccc3N3CCNCC3)N=C=C2C1=O)=N Chemical compound CNC(C1=CN(c2cc(CCC3)c3cc2)C2=NC(Nc(cc3)ccc3N3CCNCC3)N=C=C2C1=O)=N PWUBGUGRNSACJG-UHFFFAOYSA-N 0.000 description 1
- RBTDSACAVFNZRD-UHFFFAOYSA-N CNC(C1=CN(c2cc(CCC3)c3cc2)c2nc(Nc3cccc(C(N(C)C)=O)c3)ncc2C1=O)=O Chemical compound CNC(C1=CN(c2cc(CCC3)c3cc2)c2nc(Nc3cccc(C(N(C)C)=O)c3)ncc2C1=O)=O RBTDSACAVFNZRD-UHFFFAOYSA-N 0.000 description 1
- MOYHXRQYKQAYCL-UHFFFAOYSA-N CNC(C1=CN(c2ccc(CCC3)c3c2)c2nc(Nc(cc3)ccc3OCC(CN(C)C)O)ncc2C1=O)=O Chemical compound CNC(C1=CN(c2ccc(CCC3)c3c2)c2nc(Nc(cc3)ccc3OCC(CN(C)C)O)ncc2C1=O)=O MOYHXRQYKQAYCL-UHFFFAOYSA-N 0.000 description 1
- NBKLIVZCUPZPQK-UHFFFAOYSA-O CNC(C1=C[NH+](c2ccc(CCC3)c3c2)c2nc(Nc3cc(N4CCNCC4)ccc3)[n]cc2C1=O)=O Chemical compound CNC(C1=C[NH+](c2ccc(CCC3)c3c2)c2nc(Nc3cc(N4CCNCC4)ccc3)[n]cc2C1=O)=O NBKLIVZCUPZPQK-UHFFFAOYSA-O 0.000 description 1
- MRGLZVCPEUGFMA-UHFFFAOYSA-N C[N](C)(CC1)CCS1=O Chemical compound C[N](C)(CC1)CCS1=O MRGLZVCPEUGFMA-UHFFFAOYSA-N 0.000 description 1
- JVEIRUGXUUBLRS-UHFFFAOYSA-N NC(C1=CN(c2ccc(CCC3)c3c2)c2nc(Nc3ccc(C4CCNCC4)cc3)ncc2C1=O)=O Chemical compound NC(C1=CN(c2ccc(CCC3)c3c2)c2nc(Nc3ccc(C4CCNCC4)cc3)ncc2C1=O)=O JVEIRUGXUUBLRS-UHFFFAOYSA-N 0.000 description 1
- HEAHLTGDUHXTTO-UHFFFAOYSA-N O=S1(CNCC1)=O Chemical compound O=S1(CNCC1)=O HEAHLTGDUHXTTO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71452605P | 2005-09-14 | 2005-09-14 | |
US60/714,526 | 2005-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20080045279A true KR20080045279A (ko) | 2008-05-22 |
Family
ID=37672228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087008697A KR20080045279A (ko) | 2005-09-14 | 2006-09-13 | C-fms 키나제 저해제로서의5-옥소-5,8-디하이드로-피리도-피리미딘 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1937681A1 (fr) |
JP (1) | JP2009507924A (fr) |
KR (1) | KR20080045279A (fr) |
CN (2) | CN101300258A (fr) |
AU (1) | AU2006291007A1 (fr) |
BR (1) | BRPI0615838A2 (fr) |
CA (1) | CA2622725A1 (fr) |
WO (1) | WO2007033232A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7642270B2 (en) | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
TW200800983A (en) | 2005-09-14 | 2008-01-01 | Janssen Pharmaceutica Nv | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase |
WO2008055013A2 (fr) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidines comme inhibiteurs de la kinase c-fms |
CN101821266B (zh) | 2007-09-14 | 2014-03-12 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜通道调节因子的调节剂 |
GB0919274D0 (en) * | 2009-11-03 | 2009-12-16 | Univ The Glasgow | Plasma generation apparatus and use of plasma generation apparatus |
FR2955109B1 (fr) * | 2010-01-08 | 2012-09-07 | Sanofi Aventis | Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique |
EP2714652B8 (fr) * | 2011-05-27 | 2018-09-05 | Ardea Biosciences, Inc. | Synthèse chirale de n-{3,4-difluoro-2-[(2-fluoro-4-iodophényl)amino]-6-méthoxyphényl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides |
CN103435608A (zh) * | 2013-08-22 | 2013-12-11 | 中国药科大学 | 吡啶并嘧啶类plk1抑制剂及其用途 |
CA3048376A1 (fr) | 2016-12-27 | 2018-07-05 | Riken | Compose inhibiteur de signal bmp |
CN111848613B (zh) * | 2020-08-11 | 2021-09-24 | 山东大学 | 一种二芳基嘧啶骈吡啶酮类衍生物及其制备方法与应用 |
WO2023125812A1 (fr) * | 2021-12-31 | 2023-07-06 | 上海海雁医药科技有限公司 | Dérivé de pyrimidone substitué, composition pharmaceutique et utilisation médicale de celui-ci |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI0787726T1 (en) * | 1994-06-14 | 2002-04-30 | Dainippon Pharmaceutical Co., Ltd. | Novel compound, process for producing the same, and antitumor agent |
IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
JP4323574B2 (ja) * | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
ES2235353T3 (es) * | 1997-08-20 | 2005-07-01 | Warner-Lambert Company Llc | Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular. |
PL354241A1 (en) * | 1999-09-17 | 2003-12-29 | Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg | Kinase inhibitors as therapeutic agents |
DE10352979A1 (de) * | 2003-11-13 | 2005-06-09 | Merck Patent Gmbh | Pyridopyrimidinone |
-
2006
- 2006-09-13 CA CA002622725A patent/CA2622725A1/fr not_active Abandoned
- 2006-09-13 KR KR1020087008697A patent/KR20080045279A/ko not_active Application Discontinuation
- 2006-09-13 EP EP06803485A patent/EP1937681A1/fr not_active Withdrawn
- 2006-09-13 CN CNA2006800406466A patent/CN101300258A/zh active Pending
- 2006-09-13 AU AU2006291007A patent/AU2006291007A1/en not_active Abandoned
- 2006-09-13 JP JP2008531265A patent/JP2009507924A/ja active Pending
- 2006-09-13 WO PCT/US2006/035619 patent/WO2007033232A1/fr active Application Filing
- 2006-09-13 CN CNA2006800414424A patent/CN101305000A/zh active Pending
- 2006-09-13 BR BRPI0615838-2A patent/BRPI0615838A2/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2622725A1 (fr) | 2007-03-22 |
EP1937681A1 (fr) | 2008-07-02 |
CN101300258A (zh) | 2008-11-05 |
JP2009507924A (ja) | 2009-02-26 |
CN101305000A (zh) | 2008-11-12 |
AU2006291007A1 (en) | 2007-03-22 |
BRPI0615838A2 (pt) | 2011-05-31 |
WO2007033232A1 (fr) | 2007-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7642270B2 (en) | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase | |
KR20080045279A (ko) | C-fms 키나제 저해제로서의5-옥소-5,8-디하이드로-피리도-피리미딘 | |
CA2425440C (fr) | Aza- et polyaza-naphthalenyl carboxamides utiles comme inhibiteurs de l'integrase du vih | |
US20080114007A1 (en) | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | |
CA3009669C (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
JP4938651B2 (ja) | 置換フェニルアミノピリミジン化合物 | |
US7705005B2 (en) | Bicyclic heteroaromatic compounds | |
JP4309653B2 (ja) | 新規なスルホンアミド置換ピラゾロピリジン誘導体 | |
US20160264572A1 (en) | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (trk) inhibitors | |
CA2579059A1 (fr) | Composes chimiques | |
JP2009524689A (ja) | 化合物 | |
EP1838312A2 (fr) | Composes chimiques | |
TWI464170B (zh) | 5-酮基-5,8-二氫吡啶并[2,3-d]嘧啶衍生物,其製備及其治療用途 | |
EP1535922A1 (fr) | Derive de pyrrolopyridine et utilisation de ce dernier | |
WO2010026113A1 (fr) | Acyl- et sufonyl-tétrahydronaphtyridines et dérivés aza de celles-ci en tant qu’antagonistes de récepteur d’histamine h3 | |
CA3050770C (fr) | Composes et compositions pharmaceutiques pour moduler l'activite sgk, et leurs procedes | |
WO2003077857A2 (fr) | N-(benzyl substitue)-8-hydroxy-1,6-naphtyridine-7-carboxamides utiles comme inhibiteurs de l'integrase du vih | |
WO2010052222A1 (fr) | Dérivés (dihydro)naphthyridinone comme antagonistes du récepteur h3 de l’histamine | |
US7728003B2 (en) | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | |
WO2018205916A1 (fr) | Inhibiteur de fgfr4, préparation et utilisation associées | |
JP2012515186A (ja) | カテプシンS及び/又はカテプシンK阻害剤としての6−フェニル−1H−イミダゾ[4,5−c]ピリジン−4−カルボニトリル誘導体 | |
MX2008003685A (en) | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |